Last reviewed · How we verify
Placebo (canagliflozin)
Canagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and lower blood glucose.
Canagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and lower blood glucose. Used for Type 2 diabetes mellitus, Diabetic kidney disease, Heart failure with reduced ejection fraction.
At a glance
| Generic name | Placebo (canagliflozin) |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 (sodium-glucose cotransporter 2) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Canagliflozin blocks SGLT2, a transporter protein in the proximal tubule of the kidney that normally reabsorbs filtered glucose back into the bloodstream. By inhibiting this transporter, the drug allows excess glucose to be excreted in the urine, thereby reducing blood glucose levels in a glucose-dependent manner. This mechanism is independent of insulin secretion or action.
Approved indications
- Type 2 diabetes mellitus
- Diabetic kidney disease
- Heart failure with reduced ejection fraction
Common side effects
- Genital mycotic infections
- Urinary tract infections
- Polyuria
- Thirst
- Diabetic ketoacidosis
Key clinical trials
- Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis (PHASE2)
- Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide. (NA)
- Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus (PHASE4)
- An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes (PHASE2)
- Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes (PHASE3)
- Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy (PHASE3)
- Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin) (PHASE3)
- Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (canagliflozin) CI brief — competitive landscape report
- Placebo (canagliflozin) updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI